虽然传统的新冠肺炎mRNA疫苗通过S蛋白的细胞表面表达诱导抗体反应,信使核糖核酸介导的S-EABR构建体的递送可以增强B细胞的激活,因为S-EABR蛋白不仅会在细胞表面表达,还会诱导从细胞中出芽并分布在体内的eVLP的组装,以激活免疫细胞。 为了研究S-EABR-eVLP的基因编码是否能增强基于严重急性呼吸系统综合征冠状病毒2型S的mRNA...
SARS-CoV-2 S (Hexapro Delta) This paper N/A SARS-CoV-2 S (Hexapro Omicron BA.1) This paper N/A SARS-CoV-2 S (Hexapro Omicron BA.2) This paper N/A SARS-CoV-2 S (Omicron BA.4/5) Sino Biological Cat#40589-V08H32 LYRa11 S (S-2P) This paper N/A RaTG13 S (S-2P) ...
HexaPro是一种稳定的S,包含四个脯氨酸替换(F817P、A892P、A899P、A942P)以及S-2P(K986P/V987P)中的两个脯氨酸替换,还包含furin裂解位点(682-GSAS-685)和C-末端三聚基序(84)的突变。由于其高稳定性、良好的表达和改善的溶解...
NVX-CoV2373 是一种重组 SARS-CoV-2 纳米颗粒疫苗,由全长三聚体 SARS-CoV- 2 刺突蛋白(S 蛋白)和一种Novavax专有的基于皂苷的 Matrix-M1 佐剂组成。I 期 临床试验共招募 131 名 18-59 岁的成年受试者,采取间隔 21 天的 2 针免疫程序,5 微克或 25 微克剂量组以及是否含有 Matrix-M1 佐剂的试验设计。
10.1016/S2213-2600(21)00402-1 其它文件與鏈接 Link to publication in Scopus 指紋 深入研究「Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-control...
SARS-CoV-2、N蛋白、ACE2蛋白、Spike蛋白的研究日趋成熟,为遏制COVID-19的全球大流行提供了强有力的科学依据。自COVID-19疫情爆发以来,Bioss积极投身SARS-CoV-2相关抗体、重组蛋白以及ELISA检测试剂盒的研发工作,立志为科研工作者研究新型冠状病毒肺炎提供强有力的科研工具。
p3BNC-SARS-CoV-2 S-2P-ΔCT This paper N/A p3BNC-SARS-CoV-2 S-2P-ΔCT-EABR This paper N/A p3BNC-SARS-CoV-2 S-2P-ΔCT-EABR/no EPM This paper N/A p3BNC-SARS-CoV-2 S-2P-ΔCT-EABRmin1 This paper N/A p3BNC-SARS-CoV-2 S-2P-ΔCT-EABRmin2 This paper N/A p3BNC-HIV...
fashion at both 50 and 100 µg dose levels [20]. Of note, a mRNA-1273 vaccine is given in two doses by intramuscular injection separated by 28 days [50]. Interestingly, a single dose of mRNA-expressing SARS-CoV-2 S-2P has demonstrated immunogenic and neutralizing activity as well [...
There is an urgent need to create novel models using human disease-relevant cells to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) biology and to facilitate drug screening. Here, as SARS-CoV-2 primarily infects the respiratory tract,
7 mRNA-1273 and SAS-adjuvanted S-2P protein elicit both IgG2a and IgG1 subclass S-binding antibodies. a–f, BALB/cJ (a–c) or C57BL/6J (d–f) mice (n = 10/group) were immunized at weeks 0 and 3 with 0.01 (green), 0.1 (blue), or 1 μg (red) of mRNA-1273 or SARS-CoV...